Biren Amin
Stock Analyst at Piper Sandler
(2.10)
# 3,042
Out of 4,969 analysts
59
Total ratings
46.15%
Success rate
-6.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Neutral | $11 → $15 | $18.95 | -20.84% | 11 | Jul 29, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $63 → $68 | $51.84 | +31.17% | 3 | Jul 14, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $2.06 | +191.26% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.84 | +374.55% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.75 | +195.65% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.12 | +525.00% | 3 | May 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $39.27 | +29.87% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $15.91 | +138.84% | 1 | Mar 31, 2025 | |
| MNPR Monopar Therapeutics | Assumes: Overweight | $76 | $36.21 | +109.89% | 1 | Mar 19, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $3.37 | +256.08% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $26.83 | +164.63% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $9.85 | +255.33% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $10.25 | +104.88% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $71.07 | +61.81% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $27.80 | +15.11% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $4.26 | -29.58% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.95 | +15.87% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.71 | +3,993.57% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.49 | +10,340.12% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.85 | +310.61% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.90 | +1,072.41% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $15.01 | +3,231.11% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $5.44 | +157.35% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $563.80 | +22.56% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.12 | +371.70% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $22.52 | +348.59% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $136.11 | -49.31% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $396.62 | -60.92% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $2.40 | +5,566.67% | 4 | Mar 6, 2017 |
Sarepta Therapeutics
Jul 29, 2025
Maintains: Neutral
Price Target: $11 → $15
Current: $18.95
Upside: -20.84%
BridgeBio Pharma
Jul 14, 2025
Maintains: Overweight
Price Target: $63 → $68
Current: $51.84
Upside: +31.17%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $2.06
Upside: +191.26%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.84
Upside: +374.55%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.75
Upside: +195.65%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.12
Upside: +525.00%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $39.27
Upside: +29.87%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $15.91
Upside: +138.84%
Monopar Therapeutics
Mar 19, 2025
Assumes: Overweight
Price Target: $76
Current: $36.21
Upside: +109.89%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $3.37
Upside: +256.08%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $26.83
Upside: +164.63%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $9.85
Upside: +255.33%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $10.25
Upside: +104.88%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $71.07
Upside: +61.81%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $27.80
Upside: +15.11%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $4.26
Upside: -29.58%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $12.95
Upside: +15.87%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.71
Upside: +3,993.57%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.49
Upside: +10,340.12%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.85
Upside: +310.61%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.90
Upside: +1,072.41%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $15.01
Upside: +3,231.11%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $5.44
Upside: +157.35%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $563.80
Upside: +22.56%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.12
Upside: +371.70%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $22.52
Upside: +348.59%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $136.11
Upside: -49.31%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $396.62
Upside: -60.92%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $2.40
Upside: +5,566.67%